Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer’s Avelumab Poised For Speedy Review By FDA

Nov 29 2016

• By Jessica Merrill

Related Content

Pfizer sides with Merck KGaA on PD-L1; AZ deal out for good?

Nov 17 2014

It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer

Oct 25 2016

AstraZeneca Clinical Hold Could Be No Real Concern, Or Very Bad For AZ And BMS

Oct 27 2016

Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology

Aug 22 2016

FDA Continues To Speed PD-1/L1 Drugs To Market

Oct 25 2016

Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race

May 09 2016

Related Companies

Pfizer Inc.

Merck KGaA

Merck & Co., Inc.

Bristol Myers Squibb Company

Roche Holding AG

AstraZeneca PLC

Medivation, Inc.

Astellas Pharma, Inc.

Additional Topics

Companies Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window